X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs DIVIS LABORATORIES - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD DIVIS LABORATORIES ORCHID PHARMA LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 0.2 32.0 0.5% View Chart
P/BV x 0.2 5.7 3.1% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ORCHID PHARMA LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
DIVIS LABORATORIES
Mar-17
ORCHID PHARMA LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1941,222 15.9%   
Low Rs35784 4.5%   
Sales per share (Unadj.) Rs276.5153.1 180.6%  
Earnings per share (Unadj.) Rs-79.239.9 -198.3%  
Cash flow per share (Unadj.) Rs-43.544.6 -97.4%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs53.9201.8 26.7%  
Shares outstanding (eoy) m70.45265.47 26.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.46.6 6.3%   
Avg P/E ratio x-1.425.1 -5.8%  
P/CF ratio (eoy) x-2.622.5 -11.7%  
Price / Book Value ratio x2.15.0 42.7%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m8,067266,266 3.0%   
No. of employees `0002.89.7 28.8%   
Total wages/salary Rs m2,5274,687 53.9%   
Avg. sales/employee Rs Th6,956.14,175.0 166.6%   
Avg. wages/employee Rs Th902.5481.5 187.4%   
Avg. net profit/employee Rs Th-1,993.01,089.3 -183.0%   
INCOME DATA
Net Sales Rs m19,47740,643 47.9%  
Other income Rs m407749 54.4%   
Total revenues Rs m19,88441,392 48.0%   
Gross profit Rs m1,10314,460 7.6%  
Depreciation Rs m2,5191,233 204.3%   
Interest Rs m5,22723 23,127.4%   
Profit before tax Rs m-6,23613,953 -44.7%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1253,349 -3.7%   
Profit after tax Rs m-5,58010,604 -52.6%  
Gross profit margin %5.735.6 15.9%  
Effective tax rate %2.024.0 8.4%   
Net profit margin %-28.726.1 -109.8%  
BALANCE SHEET DATA
Current assets Rs m11,01440,105 27.5%   
Current liabilities Rs m32,0606,595 486.2%   
Net working cap to sales %-108.182.5 -131.1%  
Current ratio x0.36.1 5.6%  
Inventory Days Days95119 80.0%  
Debtors Days Days3481 41.6%  
Net fixed assets Rs m29,44019,995 147.2%   
Share capital Rs m705531 132.7%   
"Free" reserves Rs m2,04353,043 3.9%   
Net worth Rs m3,80053,574 7.1%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51061,585 75.5%  
Interest coverage x-0.2618.4 -0.0%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.7 63.5%   
Return on assets %-0.817.3 -4.4%  
Return on equity %-146.919.8 -741.9%  
Return on capital %-3.726.1 -14.3%  
Exports to sales %37.90-   
Imports to sales %22.625.2 89.6%   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,40610,259 42.9%   
Fx inflow Rs m7,51335,384 21.2%   
Fx outflow Rs m5,64910,399 54.3%   
Net fx Rs m1,86524,985 7.5%   
CASH FLOW
From Operations Rs m1,68211,493 14.6%  
From Investments Rs m-9,860-11,372 86.7%  
From Financial Activity Rs m6,644-93 -7,136.2%  
Net Cashflow Rs m-1,53528 -5,404.9%  

Share Holding

Indian Promoters % 32.3 52.0 62.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 11.8 39.0%  
FIIs % 3.3 19.0 17.4%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.2 321.5%  
Shareholders   84,811 31,796 266.7%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Aug 14, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - SUVEN LIFE COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS